Skip to main content
SpringerLink
Log in

Chemotherapy of Squamous Head and Neck Cancer

  • Chapter
Oral Oncology

Part of the book series: Developments in Oncology ((DION,volume 20))

  • 90 Accesses

Abstract

The role of chemotherapy in the management of cancers of the oral cavity continues to be defined through active ongoing clinical investigation. Since most series combine oral cavity with the other head and neck regions—namely, oropharynx, hypopharynx, larynx, nasopharynx, and paranasal sinuses—this chapter will review the use of chemotherapy in head and neck cancer and, where possible, cite oral cavity region-specific differences if such exist.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sako K, Lore JM, Kaufman S, et al. Parenteral hyperalimentation in surgical patients with head and neck cancer: A randomized study. J Surg Onc (16): 391–402, 1981.

    CAS  Google Scholar 

  2. Miller EM, Norman D. The role of computed tomography in the evaluation of neck masses. Radiology (133): 145–149, 1979.

    PubMed  CAS  Google Scholar 

  3. Son YH. Evaluation of neck mass: Computed tomography. Conn Med (45): 75–78, 1981.

    PubMed  CAS  Google Scholar 

  4. Baker SR, Krause CJ. Ultrasonic analysis of head and neck neoplasms. Ann Otol (90): 126–131, 1981.

    CAS  Google Scholar 

  5. Gooding GAW. Gray-scale ultrasonography of the neck. JAMA (243): 1562–1564, 1980.

    PubMed  CAS  Google Scholar 

  6. Amer MF, Al-Sarraf M, Vaitkevicius VK. Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer (43): 2202–2206, 1979.

    PubMed  CAS  Google Scholar 

  7. Cortes EP, Kalra J, Amin VC, Attie J, Eisenbad L, Khafif R, Wolk D, Aral I, Scrubba J, Akbijik N, Heller K. Chemotherapy for head and neck cancer relapsing after radiotherapy. Cancer (47): 1966–1981.

    Google Scholar 

  8. Didolkar MS, Coleman JJ, Elias EG, Gray WC, Cosentino E. Chemotherapy for advanced carcinoma of head and neck: An effective outpatient schedule of Cytoxan, Oncovin, methotrexate and bleomycin. Head & Neck Surg (4): 92–97, 1981.

    CAS  Google Scholar 

  9. Woods RL, Fox RM, Tattersall MHN. Advanced squamous cell carcinomas of the head and neck—A randomised study of three methotrexate doses. Brit Med J (282): 600–602, 1981.

    CAS  Google Scholar 

  10. Sealy R, Helman P. Treatment of head and neck cancer with intra-arterial cytotoxic drugs and radiotherapy. Cancer (30): 187, 1972.

    PubMed  CAS  Google Scholar 

  11. Wittes RE, Cvitkovic E, Shah J, et al. Cis-dichlorodiammine-platinum (II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep (61): 359–366, 1977.

    PubMed  CAS  Google Scholar 

  12. Wittes RE, Heller K, Randolph V, et al. Cis-dichlorodiammine-platinum (H)-based chemotherapy as initial treatment in advanced head and neck cancer. Cancer Treat Rep (63): 1533–1538, 1979.

    PubMed  CAS  Google Scholar 

  13. Mills EED. Intermittent intravenous methotrexate in the treatment of advanced epidermoid carcinoma. S Afr Med J (46): 398–401, 1972.

    PubMed  CAS  Google Scholar 

  14. Frei E, Blum R, Pitman SW, Kirkwood J, Henderson IC, Skarin AT, Mayer RJ, Bast R, Garnick M, Parker I, Canellos G. High-dose methotrexate with leucovorin rescue rationale and spectrum of antitumor activity. Amer J of Med (68): 270–276, 1980.

    Google Scholar 

  15. Randolph VL, Vallejo A, Spiro RH, et al. Combination therapy of advanced head and neck cancer: Induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy. Cancer (41): 460–467, 1978.

    PubMed  CAS  Google Scholar 

  16. Hong WK, Shapshay SM. Treatment of previously untreated stage III and IV squamous cell carcinoma of the head and neck. Otolaryng Clin N Am (13): 521–528, 1980.

    CAS  Google Scholar 

  17. Brown AW, Blom J, Butler W, Guerrero GG, Richardson M, Henderson RL. Combination chemotherapy with vinblastine, bleomycin, and cis-diamminedichloroplatinum (II) in squamous cell carcinoma of the head and neck. Cancer (45): 2830–2835, 1980.

    PubMed  Google Scholar 

  18. Forastiere AA, Crain SM, Coker DD, Elias EG, Amornmarn R, Wiernick PH. Cisplatin and cyclophosphamide combination chemotherapy in advanced head and neck squamous cell cancer. Proc Amer Soc Clin Onc (1): 196, 1982.

    Google Scholar 

  19. Price LA, Hill BT. Safe and effective 24-hour combination chemotherapy without cisplatin as initial treatment in head and neck cancer. Proc Amer Soc Clin Onc 1: 202, 1982.

    Google Scholar 

  20. Hill BT, Dalley VM, Shaw JH. 24-hour combination chemotherapy without cisplatin in recurrent or metastatic head and neck cancer. Proc Amer Soc Clin Onc (1): 202, 1982.

    Google Scholar 

  21. Vogl SE, Lerner H, Kaplan BH, Camacho F, Anberg J, Schoenfeld D. Mitomycin-C, methotrexate, bleomycin and cis-diamminedichloroplatinum II in the chemotherapy of advanced squamous cancer of the head and neck. Cancer (50): 6–9, 1982.

    PubMed  CAS  Google Scholar 

  22. Amer MH, Izbicki R, Vaitkevicius VK, Al-Sarraf M. Cis-diamminedichloroplatinum, Oncovin and bleomycin (COB) in advanced head and neck cancer, phase II. Cancer (45): 217–223, 1980.

    PubMed  CAS  Google Scholar 

  23. Decker DA, Drelichman A, Jacobs J, Hoschner J, Kinzie J, Loh JJK, Weaver A, Al-Sarraf M. Adjuvant chemotherapy with high dose bolus cis-diammindichloroplatinum II and 120 hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Proc Amer Soc Clin Onc (1): 195, 1982.

    Google Scholar 

  24. Kish J, Drelichman A, Weaver A, Jacobs J, Bergsman K, Al-Sarraf M. Cis-platinum and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Proc Amer Soc Clin Onc (1): 193, 1982.

    Google Scholar 

  25. Ervin RJ, Weichselbaum R, Miller D, et al. Treatment of advanced squamous cell carcinoma of the head and neck with cis-platin, bleomycin, and methotrexate (PBM). Cancer Treat Rep (65): 787–791, 1981.

    PubMed  CAS  Google Scholar 

  26. Molinari R, Mattavelli F, Cantu G, Chiesa F, Costa L, Tancini G. Results of a low-dose combination chemotherapy with vincristine, bleomycin and methotrexate (V-B-M) based on cell kinetics in the palliative treatment of head and neck squamous cell carcinoma. Eur J Cancer (16): 469–472, 1980.

    PubMed  CAS  Google Scholar 

  27. DeConti RC, Schoenfeld D. A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin and a methotrexate combination in head and neck cancer. Cancer (48): 1061–1072, 1981.

    PubMed  CAS  Google Scholar 

  28. Coker DD, Elias EG, Chretien PB, Gray WC, Coleman JJ, Zentai TA, Didolkar MS, Morris DM, Viravathana T, Hebel JR. Combination chemotherapy for advanced squamous cell carcinoma of the head and neck. Head & Neck Surg (4): 111–117, 1981.

    CAS  Google Scholar 

  29. Williams SD, Einhorn LH, Velez-Garcia E, Essessee I, Ratkin G, Birch R, Garrard J. Chemotherapy of head and neck cancer: Comparison of cisplatin and vinblastine and bleomycin (PVB) versus methotrexate (MTX). Proc Amer Soc Clin Onc (1): 202, 1982.

    Google Scholar 

  30. Woods RL, Fox RM, Tattersall MHN. Methotrexate treatment of advanced head and neck cancers: A dose response evaluation. Cancer Treat Rep (65) (Suppl): 155–159, 1981.

    PubMed  Google Scholar 

  31. Bertino JR, Boston B, Capizzi RL. The role of chemotherapy in the management of cancer of the head and neck: A review. Cancer (36): 752–758, 1975.

    PubMed  CAS  Google Scholar 

  32. Creagan ET, Fleming TR, Edmonson JH, Ingle J, Woods JE. Cyclophosphamide, adriamy-cin and cis-dichlorodiammineplatinum II in the treatment of patients with advanced head and neck cancer. Cancer (47): 240–244, 1981.

    PubMed  CAS  Google Scholar 

  33. Presant CA, Ratkin G, Klahr C et al. Adriamycin, BCNU plus cyclophosphamide (ABC) in advanced carcinoma of the head and neck. Cancer (44): 1571–1575, 1979.

    PubMed  CAS  Google Scholar 

  34. Jorgensen K, Schlichting J. Relationship between histologic grading of head and neck tumours and regression after chemotherapy. Acta Radiologica Oncology (19): 357–359, 1980.

    PubMed  CAS  Google Scholar 

  35. Ohnuma, A. Effects of combination therapy with bleomycin (NSC-125066) and dibromodulcitol (NSC-104800) on squamous cell carcinoma in man. Cancer Chem. rep. (56): 625–633, 1972.

    Google Scholar 

  36. Papac RJ, Lefkowitz E, Bertino JR. Methotrexate (NSC-740) in squamous cell carcinoma of the head and neck. II. Intermittent intravenous therapy. Cancer Chemother Rep (51): 69–72, 1967.

    Google Scholar 

  37. Lane M, Moore JE, Levin H et al. Methotrexate therapy for squamous cell carcinoma of the head and neck. JAMA (204): 561–564, 1968.

    PubMed  CAS  Google Scholar 

  38. Leone LA, Albala MM, Rege VB. Treatment of carcinoma of the head and neck with intravenous methotrexate. Cancer (21): 828–837, 1968.

    PubMed  CAS  Google Scholar 

  39. DePalo GM, DeLana M, Molinari R, et al. Clinical evaluation of high weekly intravenous doses of methotrexate in advanced oropharyngeal carcinoma. Tumori (56): 259–268, 1970.

    CAS  Google Scholar 

  40. Papac R, Minor DR, Rudnick S, et al. Controlled trial of methotrexate and Bacillus Calmette-Guarin therapy for advanced head and neck cancer. Cancer Res (38): 3150–3153, 1978.

    PubMed  CAS  Google Scholar 

  41. Vogler WR, Jacobs J, Moffitt S, Velez-Garcia E, Goldsmith A, Johnson L, Mackay S. Methotrexatee therapy with or without citrovorum factor in carcinoma of the head and neck, breast, and colon. Cancer Clin Trials (2): 227–236, 1979.

    Google Scholar 

  42. Woods. Personal communication.

    Google Scholar 

  43. Hong WK, Schaefer S, Issell B, Cummings C, Luedka D, Bromer R, Lavin L. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinomas of the head and neck. Proc Amer Soc Clin Onc (1): 202, 1982.

    Google Scholar 

  44. Vogl. Personal communication.

    Google Scholar 

  45. Vogl. Personal communication.

    Google Scholar 

  46. Goldsmith MA, Carter S. The integration of chemotherapy into a combined modality approach to cancer therapy. V. Squamous cell cancer of the head and neck. Cancer Treat Rev (2): 137–158, 1975.

    PubMed  CAS  Google Scholar 

  47. Huseby RA, Downing V. The use of methotrexate orally in treatment of squamous cancers of the head and neck. Cancer Chemother Rep (16): 511–514, 1962.

    PubMed  CAS  Google Scholar 

  48. Papac RJ, Jacobs EM, Foye LV Jr, et al. Systemic therapy with amethopterin in squamous carcinoma of the head and neck. Cancer Chemother Rep (32): 47–54, 1963.

    PubMed  CAS  Google Scholar 

  49. Hellman S, Iannotti At, Bertino JR. Determination of the levels of serum folate in patients with carcinoma of the head and neck treated with methotrexate. Cancer Res (24): 105–113, 1964.

    PubMed  CAS  Google Scholar 

  50. Vogler WR, Huseby CM Jr, Kerr W. Toxicity and antitumor effect of divided doses of methotrexate. Arch Intern Med (115): 285–293, 1965.

    PubMed  CAS  Google Scholar 

  51. Kligerman MM, Hellman S, VonEssen DE, et al. Sequential chemotherapy and radiotherapy. Radiology (87): 247–250, 1966.

    Google Scholar 

  52. Andrews NC, Wilson WL. Phase II study of methotrexate (NSC-740) in solid tumors. Cancer Chemother Rep (51): 471–474, 1967.

    Google Scholar 

  53. Sullivan RD, Miller E, Sires MP. Antimetabolite-metabolite combination cancer chemotherapy—effects of intra-arterial methotrexate intramuscular citrovorum factor therapy in human cancer. Cancer (12): 1248–1262, 1959.

    PubMed  CAS  Google Scholar 

  54. Capizzi RL, DeConti RC, Marsh JC, Bertino JR. Methotrexate therapy of head and neck cancer: Improvement in therapeutic index by the use of leucovorin “rescue.” Cancer Res (30): 1782–1788, 1970.

    PubMed  CAS  Google Scholar 

  55. Kirkwood JM, Canellos GP, Ervin TJ, Pitman SW, Weichelsbaum R, Miller D. Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs weekly high-dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: A safe new effective regimen. Cancer (47): 2414–2421, 1981.

    PubMed  CAS  Google Scholar 

  56. Pitman SW, Parker LM, Tattersall MHN, Jaffe N, Frei E. Clinical trial of high-dose methotrexate (NSC-740) with citrovorum factor (NSC-3590)—Toxiologic and therapeutic observations. Cancer Chemo Rep (6): 43–49, 1975.

    Google Scholar 

  57. Condit PT, Chang RE, Joel W. Renal toxicity of methotrexate. Cancer (23): 126–131, 1969.

    PubMed  CAS  Google Scholar 

  58. Stoller RG, Jacobs SA, Drake JC, et al. Pharmacokinetics of high-dose methotrexate. Cancer Chemother Rep (6): 19–24, 1975.

    Google Scholar 

  59. Pitman SW, Frei E III. Weekly methotrexate-calcium leucovorin rescue. I. Effects of alkalinization on nephrotoxicity. Cancer Treat Rep (61): 695–701, 1977.

    PubMed  CAS  Google Scholar 

  60. Stoller RG, Hander KR, Jacobs SA, et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med (297): 630–634, 1977.

    PubMed  CAS  Google Scholar 

  61. Levitt M, Mosher MB, DeConti RC, Farber LR, Skeel RT, Marsh JC, Mitchell MS, Papac RJ, Thomas ED, Bertino JR. Improved therapeutic index of methotrexate with “leucovorin rescue.” Cancer Res (33): 1729–1734, 1973.

    PubMed  CAS  Google Scholar 

  62. Krishan A, Pitman S, Tattersall MHN, et al. Flow micro-fluorometric patterns of human bone marrow and tumor cells in response to cancer chemotherapy. Cancer Res (36): 3813–3820, 1976.

    PubMed  CAS  Google Scholar 

  63. Jaffe N, Frei E III, Traggis D, et al. Weekly high-dose methotrexate citrovorum factor in osteogenic sarcoma: Pre-surgical treatment of primary tumor and of overt pulmonary metastases. Cancer (39): 145–150, 1977.

    Google Scholar 

  64. Bertino JR. The mechanism of action of the folate antagonists in man. Cancer Res (23): 1286–1306, 1963.

    PubMed  CAS  Google Scholar 

  65. Goldman ID, Lichenstein NS, Oliverio VT. Carrier mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem (243): 5007–5017, 1968.

    PubMed  CAS  Google Scholar 

  66. Nahas A, Nixon PE, Bertino JR. Uptake and metabolism of N5formyltetrahydrofolate by L1210 leukemia cells. Cancer Res (32): 1416–1421, 1972.

    PubMed  CAS  Google Scholar 

  67. Huennekens FM, Vitols KS, Henderson GB. Transport of folate compounds in bacterial and mammalian cells. Adv in Enzymology: 313–344, 1978.

    Google Scholar 

  68. Baugh CM, Krumdieck CL, Nair MG. Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun (52): 27–34, 1973.

    PubMed  CAS  Google Scholar 

  69. Jacobs SA, Adamson RH, Chabner BA, Derr CJ, Johns DG. Stoichiometric inhibition of mammalian dihydrofolate reductase by the -glutamyl metabolite of methotrexate, 4-amino-4-deoxy-N10-methyl-pteroylglutamyl-glutamate. Biochem Biophys Res Comm (63): 692–798, 1975.

    PubMed  CAS  Google Scholar 

  70. Hryniuk WM, Fischer GA, Bertino JR. S-phase cells of rapidly growing and resting populations. Differences in response to methotrexate. Biol Pharmacol (5): 57–64, 1969.

    Google Scholar 

  71. Henderson ES, Adamson RH, Oliverio VT. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res (25): 1018–1024, 1965.

    PubMed  CAS  Google Scholar 

  72. Chungi VS, Bourne DWA, Dittert LW. Drug absorption VIII: Kinetics of GI absorption of methotrexate. J Pharmaceutic Sci (67): 560–561, 1978.

    CAS  Google Scholar 

  73. Pinkerton CR, Welshman SG, Dempsey SI, Bridges JM, Glasgow JFT. Absorption of methotrexate under standardized conditions in children with acute lymphoblastic leukeaemia. Br J Cancer (42): 613–615, 1980.

    PubMed  CAS  Google Scholar 

  74. Huffman D, Wan SH, Azarnoff DL, Hoogstraten B. Pharmacokinetics of methotrexate. Clin Pharmacol Ther (14): 572–579, 1973.

    PubMed  CAS  Google Scholar 

  75. Bischoff KG, Dedrick RL, Zaharko DS, Longstreth JA. Methotrexate pharmacokinetics. J Pharmaceutic Sci (60): 1128–1133, 1971.

    CAS  Google Scholar 

  76. Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. Clin Invest (52): 1804–1811, 1973.

    CAS  Google Scholar 

  77. Chabner BA, Johns DG, Bertino JR. Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature 239: 395–397, 1972.

    PubMed  CAS  Google Scholar 

  78. Creaven PJ, Hansen HH, Alford DA, Allen LM. Methotrexate in liver and bile after intravenous dosage in man. Br J Cancer (28): 589–591, 1973.

    PubMed  CAS  Google Scholar 

  79. Gewirtz DA, White JC, Randolph JK, Goldman ID. Transport, binding and polyglutamylation of methotrexate in freshly isolate rat hepatocytes. Cancer Res (40): 573–578, 1980.

    PubMed  CAS  Google Scholar 

  80. Kamen BA, Nylen PA, Camitta BM, Bertino JR. Methotrexate accumulation in cells as possible mechanism of chronic toxicity to the drug. Br J Hematol, in press.

    Google Scholar 

  81. Wan SH, Huffman DH, Azarnoff D, Stephens R, Hoogstraten B. Effect of route of administration and effusion on methotrexate pharmacokinetics. Cancer Res (34): 3487–3491, 1974.

    PubMed  CAS  Google Scholar 

  82. Valerino DM, Johns DG, Zaharko DS, Oliverio VT. Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N10-methylpteroid acid. Biochem Pharmacol (21): 821–831, 1972.

    PubMed  CAS  Google Scholar 

  83. Jacobs SA, Stoller RG, Chabner BA, Johns DG. 7-hydroxymethotrexate as a urinary metabolite in human subjects and Rhesus monkeys receiving high-dose methotrexate. J Clin Invest (57): 534–538, 1976.

    PubMed  CAS  Google Scholar 

  84. Huang KC, Enczak BA, Liu YK. Renal tubular transport of methotrexate in the Rhesus monkey and dog. Cancer Res (39): 4838–4848, 1979.

    Google Scholar 

  85. Rosenberg B, Van Camp L, Krigos T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature (205): 698–699, 1965.

    PubMed  CAS  Google Scholar 

  86. Rosenzweig M, Von Hoff DD, Slavik M et al. Cis-diamminedichloroplatinum II. Annals Int Med (86): 803–812, 1977.

    Google Scholar 

  87. Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, King JI. Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer (59): 647–659, 1975.

    CAS  Google Scholar 

  88. Jacobs C, Bertino JR, Goffinet DR, FU WW, Goode RL. 24-hour infusion of cis-platinum in head and neck cancers. Cancer (42): 2135–2140, 1978.

    PubMed  CAS  Google Scholar 

  89. Sako K, Rizack MS, Kalmens I. Chemotherapy for advanced and recurrent squamous cell carcinoma of the head and neck with high and low dose cis-diamminedichloroplatinum. Am J Surg (136): 529–533, 1978.

    PubMed  CAS  Google Scholar 

  90. Hayat M, Bayssas M, Brule G, et al. Cis-platinum-diamminodichloro (CDDP) in chemotherapy of cancers. Biochemic (60): 935–940, 1978.

    Google Scholar 

  91. Aribas E. Personal communication.

    Google Scholar 

  92. Davis S, Kessler W. Randomized comparison of cis-diamminedichloroplatinum vs cis-diamminedichloroplatinum, methotrexate and bleomycin in recurrent squamous cell carcinoma of the head and neck. Cancer Chemo Pharmacol (3): 57–59, 1979.

    CAS  Google Scholar 

  93. Pannettiere FJ, Lehane D, Fletcher WS, et al. Cis-platinum therapy of previously treated head and neck cancer: The Southwest Oncology Group’s two-dose-per-month outpatient regimen. Med Pediatr Oncol (8): 221–225, 1980.

    Google Scholar 

  94. Drewinko B, Brown BW, Gottlieb JA. The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res (33): 3091–3095, 1973.

    PubMed  CAS  Google Scholar 

  95. Deconti RC, Toftness BR, Lange RC, et al. Clinical and pharmacological studies with cis-diamminedichloroplatinum II. Cancer Res (33): 1310–1315, 1973.

    PubMed  CAS  Google Scholar 

  96. Ward JM, Arabin ME, Berlin E, et al. Prevention of renal failure in rats receiving cis-diamminedichloroplatinum (II) by administration of furosemide. Cancer Res (37): 1238–1240, 1977.

    PubMed  CAS  Google Scholar 

  97. Hayes DM, Critkovic E, Golbey RB, et al. High-dose cis-platinumdiamminedichloride. Cancer (39): 1372–1381, 1977.

    PubMed  CAS  Google Scholar 

  98. Chary KK, Higby DJ, Henderson ES, et al. Phase I Study of high dose cis-dichlorodiammine platinum (II) with forced diuresis. Cancer Treat Rep (61): 367–370, 1977.

    PubMed  CAS  Google Scholar 

  99. Ozols RF, Javadpour N, Messerschmidt EL, Young RC. Poor prognosis non-seminomatous testicular cancer: An effective “high-dose” cis-platinum regimen without increased renal toxicity. Proc Amer Soc Clin Oncol (1): 113, 1982.

    Google Scholar 

  100. Umezawa H. Chemistry and mechanism of action of bleomycin. Fed Proc (33): 2296–2307, 1976.

    Google Scholar 

  101. Sikic BI et al. Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep 62: 2011–2017, 1978.

    PubMed  CAS  Google Scholar 

  102. Krakoff IH, Critkovic E, Currie E, Yeh S, Lamonte C. Clinical, pharmacologic and therapeutic studies of bleomycin given by continuous infusion. Cancer (40): 2027–2037, 1977.

    PubMed  CAS  Google Scholar 

  103. Byfield JE, Lee YC, Tu L, et al. Molecular interactions of the combined effects of bleomycin and x-ray on mammalian cell survival. Cancer Res (36): 1138–1143, 1976.

    PubMed  CAS  Google Scholar 

  104. Holoye PT, Broughton A, Strong JE, et al. Bleomycin: Pharmacokinetics of continuous intravenous infusion. Proc Amer Assoc for Canc Res (17): 70, 1977.

    Google Scholar 

  105. Broughton A, Strong JE. Radioimmunoassay of bleomycin. Cancer Res (36): 1418–1421, 1976.

    PubMed  CAS  Google Scholar 

  106. Blum RH, Carter SK, Agre K. A clinical review of bleomycin: A new antineoplastic agent. Cancer (31): 903–913, 1973.

    PubMed  CAS  Google Scholar 

  107. Bertino JR, Mosher MD, DeConti RC. Chemotherapy of cancer of the head and neck. Cancer (31): 1141–1149, 1973.

    PubMed  CAS  Google Scholar 

  108. Moertel CG. Clinical management of advanced gastrointestinal cancer. Cancer (36): 675–682, 1975.

    PubMed  CAS  Google Scholar 

  109. Johnson RD, Kisken WA, Curreri A. Squamous cell carcinoma of the oral cavity. Arch Surg (90): 760–763, 1965.

    PubMed  CAS  Google Scholar 

  110. Heidelberger C. Fluorinated pyrimidines and their nucleosides. In Handbook of Experimental Pharmacology, Sartorelli and Johns (ed), New York: Springer-Verlag, pp. 193–231, 1974.

    Google Scholar 

  111. Goulean M, Bleile B, Tseng BY. Methotrexate-induced misincorporation of uracil into DNA. Proc Natl Acad Sci (77): 1956–1960, 1980.

    Google Scholar 

  112. Bertino JR, Sawicki WL, Lindquist CA, Gupta VS. Schedule dependent effects of methotrexate and 5-fluorouracil. Cancer Res (37): 327–328, 1977.

    PubMed  CAS  Google Scholar 

  113. Fernandez DJ, Bertino JR. 5-fluorouracil-methotrexate synergy: Enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. Proc Nat’l Acad Sci (USA) (77): 5663–5667, 1980.

    Google Scholar 

  114. Cadman E, Heimer R, Davis L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism. (205): 1135–1137, 1979.

    CAS  Google Scholar 

  115. Cooper GM, Dunning WF, et al. Role of catabolism in pyrimidine utilization for nucleic acid synthesis in vivo. Cancer Res (32): 390–397, 1972.

    PubMed  CAS  Google Scholar 

  116. Finn C, Sadee W. Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. Cancer Chem Rep (59): 279–286, 1975.

    CAS  Google Scholar 

  117. Chaudhuri NK, Montag BJ, Heidelberger C. Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2–14C and 5-fluorourotic acid-2–14C in vivo. Cancer Res (18): 318–328, 1958.

    PubMed  CAS  Google Scholar 

  118. Clarkson B, O’Connor A, Winston, et al. The physiologic disposition of 5-fluorouracil and t-fluoro-21deoxyuridine in man. Clin Pharmacol Ther (5): 581–610, 1965.

    Google Scholar 

  119. Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurology (32): 155–160, 1970.

    Google Scholar 

  120. Wolf GT, Chretien PB. The chemotherapy and immunotherapy of head and neck cancer. In Cancer of the Head and Neck, JR Suen and EN Myers (eds). New York: Churchill-Livingstone, 1981.

    Google Scholar 

  121. Medenica R, Alberto P, Lehman W. Traitement des carcinomes epidermoides oro-pharyngo-larynges dissemines par combinaison de methotrexate et de bleomycine a petites doses. Schwerz Med Wochesnchr (106): 799–802, 1976.

    CAS  Google Scholar 

  122. Yagoda A, Lippman AJ, Winn RF, et al. Combination chemotherapy with bleomycin (BLM) and methotrexate (MTX) in patients with advanced epidermoid carcinomas. Proc Am Assoc Cancer Res (16): 247, 1975.

    Google Scholar 

  123. Lekich JJ, Frei E III. Phase II study of concurrent methotrexate and bleomycin chemotherapy. Cancer Res (34): 2240–2242, 1974.

    Google Scholar 

  124. Mosher MB, DeConti RC, Bertino JR. Bleomycin therapy in advanced Hodgkin’s disease and epidermoid cancers. Cancer (30): 56–60, 1972.

    PubMed  CAS  Google Scholar 

  125. Broquet MA, Jacot-des-Combes E, Montandon A, et al. Traitement des carcinomes epidermoides oro-pharyngo-larynges par combinaison de methotrexate et de bleomycine. Schwerz Med Wocheschr (104): 18–22, 1974.

    CAS  Google Scholar 

  126. Medenica R, Albert P, Lehmann W. Combined chemotherapy of head and neck squamous cell carcinomas with methotrexate, bleomycin and hydroxyurea. Cancer Chemother Pharmacol (5): 145–149, 1981.

    PubMed  CAS  Google Scholar 

  127. Jacobs C. High-dose methotrexate and cis-platinum in the treatment of recurrent head and neck cancer. Rec Res Can Res (76): 290–295, 1981.

    CAS  Google Scholar 

  128. Pitman SW, Minor DR, Papac R, et al. Sequential methotrexate leucovorin (MTX-LCV) and cis-platinum (CDDP) in head and neck cancer. Proc Am Assoc Cancer Res (20): 419, 1979.

    Google Scholar 

  129. Chandler JR, Tejada FJ. Triple therapy for advanced cancer of the head and neck. Arch Otolaryngol (107): 27–29, 1981.

    PubMed  CAS  Google Scholar 

  130. Elias EG, Chretien PB, Monnard E, et al. Chemotherapy prior to local therapy in advanced squamous cell carcinoma of the head and neck. Preliminary assessment of an intensive drug regimen. Cancer (43): 1025–1031, 1979.

    PubMed  CAS  Google Scholar 

  131. Caradonna R, Paladine W, Ruckdeschel JC, et al. Methotrexate, bleomycin and high-dose cis-dichlorociammineplatinum (II) in the treatment of advanced epidermoid carcinomas of the head and neck. Cancer Treat Rep (63): 489–491, 1979.

    PubMed  CAS  Google Scholar 

  132. Vogl SH, Kaplan BH. Chemotherapy of advanced head and neck cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II in an effective outpatient schedule. Cancer (44): 26–31, 1979.

    PubMed  CAS  Google Scholar 

  133. Ervin TJ, Weichselbaum R, Miller D, et al. Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and MTX (PBM). Cancer Treat Rep (65): 787–791, 1981.

    PubMed  CAS  Google Scholar 

  134. Creagan E, Fleming T, Edmonson J, Ingle J, Woods J. Chemotherapy for advanced head and neck cancer with the combination adriamycin, cyclophosphamide and cis-diammine-dichloroplatinum (II): Preliminary assessment of a one-day vs. three day drug regimen. Cancer (47): 2549–2551, 1981.

    PubMed  CAS  Google Scholar 

  135. Holoye PY, Byers RM, Gard DA, Goepfert H, Guillamondegui OM, Jesse RH. Combination chemotherapy of head and neck cancer. Cancer (42): 1661–1669, 1978.

    PubMed  CAS  Google Scholar 

  136. Plasse T, Ohnuma T, Goldsmith MA, Brooks S, Holland JF, Biller H. Bleomycin infusion followed by cyclophosphamide, methotrexate and fluorouracil in patients with head and neck cancer. Proc Amer Soc Clin Onc (1): 194, 1982.

    Google Scholar 

  137. Glick JH, Marcial V, Richter M, Velez-Garcia E. The adjuvant treatment of inoperable stage III and IV epidermoid carcinoma of the head and neck with platinum and bleomycin infusions prior to definitive radiotherapy: An RTOG pilot study. Cancer (46): 1919–1924, 1980.

    PubMed  CAS  Google Scholar 

  138. Wolf GT, Makuch RW. Pre-operative cis-platinum (CDDP) and bleomycin (BLM) in patients with head and neck squamous carcinoma (HNSCC). Proc Am Soc Clin Onc (20): 400, 1980.

    Google Scholar 

  139. Pitman SW, Kowal CD, Papac RJ, et al. Sequential methotrexate-5-fluorouracil: A highly active drug combination in advanced squamous cell carcinoma of the head and neck. Proc Amer Soc Clin Onc (20): 473, 1980.

    Google Scholar 

  140. Ringborg U, Ewert J, Kinneman J, Lundquist PG, Strander H. Sequential methotrexate-5-fluorouracil treatment of advanced carcinoma of the head and neck. UICC Conf on Clin Onc (14): 1981.

    Google Scholar 

  141. Price LA, Hill BT, Calvert AG, et al. Kinetically based multiple drug treatment for advanced head and neck cancer. Br J Med (3): 10–11, 1975.

    CAS  Google Scholar 

  142. Tannock I, Sutherland D, Osoba D. Failure of short-course multiple drug chemotherapy to benefit patients with recurrent or metastatic head and neck cancer. Cancer (49): 1358–1361, 1982.

    PubMed  CAS  Google Scholar 

  143. Corbett TH, Griswold DP, Mayo JG, et al. Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors. Cancer Res (35): 1568–1573, 1975.

    PubMed  CAS  Google Scholar 

  144. Forastiere AA, Young CW, Wittes RE. A phase II trial of m-AMSA in head and neck cancer. Cancer Chemo Pharmacol (6): 145–146, 1981.

    CAS  Google Scholar 

  145. Cheng E, Currie V, Wittes RE. Phase II trial of pyrazofurin in advanced head and neck cancer. Cancer Treat Rep (63): 2047–2048, 1979.

    PubMed  CAS  Google Scholar 

  146. Edmonson JH, Frytak S, Letendre L, Kvols LK, Egan RT. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas. Cancer Treat Rep (63): 2081–2083, 1979.

    PubMed  CAS  Google Scholar 

  147. Byrne R, Popkin J, Licciardello J, Bromer R, Weinger R, Hong W. Continuous 48-hour infusion of vindesine (DVA) in head and neck squamous cell carcinoma. Proc Amer Soc Clin Onc (1): 194, 1982.

    Google Scholar 

  148. Snow JB, Gelber RD, Kramer S, et al. Comparison of preoperative and postoperative radiation therapy for patients with carcinoma of the head and neck. Interim Report. Acta Otolaryngol (91): 611–626, 1981.

    PubMed  CAS  Google Scholar 

  149. Abe M, Shigematsu Y, Kimura S. Combined use of bleomycin with radiation in the treatment of cancer. Recent Res Cancer Res (63): 2, 169–178, 1978.

    Google Scholar 

  150. Lo T, Wiley AL, Ansfield FJ, Brandenburg JH, Davis HL, Gollin FF, Johnson RO, Famirez G, Vermund H. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: A randomized study. Cancer (126): 229–235, 1976.

    CAS  Google Scholar 

  151. Bagshaw MA, Doggett RLS. A clinical study of chemical radiosensitization. In Frontiers of Radiation Therapy and Oncology, Korger S, Vaeth JM (eds). Baltimore: University Park Press, 1969, pp. 164–173.

    Google Scholar 

  152. Cachin Y, Jortay A, Sancho H, et al. Preliminary results of a randomized EORTC study comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epidermoid carcinomas of the oropharynx. Eur J Cancer (13): 1389–1395, 1977.

    PubMed  CAS  Google Scholar 

  153. Condit PT. Treatment of carcinoma with radiation therapy and methotrexate. Missouri Med (65): 832–835, 1968.

    PubMed  CAS  Google Scholar 

  154. Kapstad B, Bang G. Rennaes S, et al. Combined preoperative treatment with cobalt and bleomycin in patients with head and neck carcinoma: A controlled clinical study. Int J Radiat Oncol Biol Phy 4: 85–89, 1978.

    CAS  Google Scholar 

  155. Richards GJ Jr, Chambers RG. Hydroxyurea: A radiosensitizer in the treatment of neoplasms of the head and neck. AJR (105): 555–565, 1969.

    Google Scholar 

  156. Stefani S, EElls RW, Abbate J. Hydroxyurea and radiotherapy in head and neck cancer: Results of prospective controlled study in 126 patients. Radiology (101): 391–396, 1971.

    PubMed  CAS  Google Scholar 

  157. Knowlton AH, Percarpio B, Bobrow S, et al. Methotrexate and radiation therapy in the treatment of advanced head and neck tumors. Radiology (116): 709–712, 1975.

    PubMed  CAS  Google Scholar 

  158. Kramer S. Methotrexate and radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, oropharynx, supraglottic larynx and hypopharynx (Preliminary report of a controlled clinical trial of the Radiation Therapy Oncology Group). Can J Otolaryngol (4): 213–218, 1975.

    PubMed  CAS  Google Scholar 

  159. Arien M. High-dose methotrexate in preoperative management. MY State J Med, 1384–1389, 1979.

    Google Scholar 

  160. Marcial VA, Velez-Garcia E, Figueroa-Valles NR, Cintron J, Vallecillo LA. Multidrug chemotherapy (vincristine-bleomycin-methotrexate) followed by radiotherapy in inoperable carcinomas of the head and neck: Preliminary report of a pilot study of the Radiation Therapy Oncology Group. Int J Radiation Oncology Biol Phys (6): 717–721, 1980.

    CAS  Google Scholar 

  161. Spaulding MB, Klotch D, Grillo J. Adjuvant chemotherapy in the treatment of advanced tumors of the head and neck. Amer J Surg (140): 538–542, 1980.

    PubMed  CAS  Google Scholar 

  162. Vogl SE, Lerner H, Kaplan BH, et al. Failure of effective initial chemotherapy to modify the course of stage IV (MO) squamous cancer of the head and neck. Cancer (50): 840–844, 1982.

    PubMed  CAS  Google Scholar 

  163. Tannock I, Cummings B, Sorrenti V, et al. Combination chemotherapy used prior to radiation therapy for locally advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep (66): 1421–1424, 1982.

    PubMed  CAS  Google Scholar 

  164. Rygaard J, Hansen HS. Bleomycin as adjuvant in radiation therapy of advanced squamous carcinoma in head and neck. Acta Otolaryngol Suppl (36): 161–166, 1979.

    Google Scholar 

  165. Ervin T, Kirkwood J, Weichselbaum R, Miller D, Pitman SW, Frei E. Improved survival for patients with advanced carcinoma of the head and neck treated with methotrexate-leucovorin prior to definitive radiotherapy or surgery. Laryngoscope (41): 1181–1190, 1981.

    Google Scholar 

  166. Richard JM, Snow GB. Present role of chemotherapy in head and neck cancer. Amsterdam Excerpta Medica, 14–21, 1975.

    Google Scholar 

  167. Schouwenburg, PF, van Putten LM, Snow GB. External carotid artery infusion with single and multiple drug regimens in the rat. Cancer (45): 2258–2264, 1980.

    PubMed  CAS  Google Scholar 

  168. Nervi C, Arcangeli G, Badaracco G. The relevance of tumor size and cell kinetics as predictors of radiation response in head and neck cancer. Cancer (41): 900–906, 1978.

    PubMed  CAS  Google Scholar 

  169. Horn Y, Adam Y, Walack N, et al. Long-term remission of an advanced head and neck tumor following intra-arterial infusion with cis-dichlorodiammineplatinum. J Surg Onc (18): 189–192, 1981.

    CAS  Google Scholar 

  170. Baker SR, Wheeler RH, Ensminger ND. Intra-arterial infusion chemotherapy for head and neck cancer using a totally implantable infusion pump. Head and Neck Surg (5): 118–124, 1981.

    Google Scholar 

Download references

Authors
  1. Susan W. Pitman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph R. Bertino
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Oral Pathology, Free University Hospital, 1117 de Boelelaan, 1007 MB, Amsterdam, The Netherlands

    I. van der Waal (Professor and Head) & G. B. Snow (Professor and Head) (Professor and Head) &  (Professor and Head)

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Martinus Nijhoff Publishing, Boston

About this chapter

Cite this chapter

Pitman, S.W., Bertino, J.R. (1984). Chemotherapy of Squamous Head and Neck Cancer. In: van der Waal, I., Snow, G.B. (eds) Oral Oncology. Developments in Oncology, vol 20. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2845-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2845-2_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9796-3

  • Online ISBN: 978-1-4613-2845-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation